Syncell Inc
- 12/12/2024
- Series A
- $15,000,000
Syncell is a life science tools company revolutionizing proteome and biomarker discovery. Imagine that you have a subcellular “pickable” microscope to let you isolate and identify proteins at a specific location you like under the microscope. Syncell’s groundbreaking Microscoop platform enables hypothesis-free subcellular spatial proteomics with high sensitivity and specificity. Researchers are able to use Syncell Microscoop to discover proteins novel at specific locations of interest from cell and tissue samples. This pioneering technology revolutionizes how novel molecular mechanisms can be identified and how novel biomarkers can be revealed for diseases.
- Industry Biotechnology Research
- Website https://www.syncell.com/
- LinkedIn https://www.linkedin.com/company/syncell/
Related People
Jung-Chi LiaoFounder
Dr. Jung-Chi (JC) Liao founded Syncell in 2020 and has been serving as the CEO since 2021. As a professor-inventor-entrepreneurial CEO, JC has been leading the company from R&D to commercialization of their pioneering spatial proteomics technology within four years. He defined the market needs from more than 20 years of biological research experiences and built out the strategy for production and global sales expansion. Enthusiastic responses from academia, hospitals, and pharmaceutical companies around the world were received to access Syncell’s Microscoop technology to elucidate functional biology and facilitate the findings of potential novel drug targets and disease-associated biomarkers. Prior to Syncell, JC served as a faculty member of Columbia University and Academia Sinica known for super-resolution microscopy on cell biology applications. JC did postdoctoral research at Stanford and UC Berkeley and received his M.S. and Ph.D. from MIT.